Mark Schleiss

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV)
    Mark R Schleiss
    Division of Infectious Diseases, Children s Hospital Research Foundation, Cincinnati, OH 45229, USA
    J Clin Virol 25:S37-49. 2002
  2. ncbi request reprint An animal model of neonatal cytomegalovirus infection
    Fernando J Bravo
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
    Antiviral Res 60:41-9. 2003
  3. pmc Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83)
    Alistair McGregor
    Division of Infectious Diseases, Children s Hospital Medical Center Research Foundation, University of Cincinnati, OH 45229, USA
    J Virol 78:9872-89. 2004
  4. ncbi request reprint Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects
    Mark R Schleiss
    Division of Infectious Diseases, 3333 Burnet Avenue, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Vaccine 23:687-92. 2004
  5. ncbi request reprint Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection
    Mark R Schleiss
    Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
    J Infect Dis 195:789-98. 2007
  6. pmc Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model
    Mark R Schleiss
    Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Minneapolis, United States Electronic address
    Vaccine 32:2756-62. 2014
  7. pmc Complete genome sequence of pathogenic Guinea pig cytomegalovirus from salivary gland homogenates of infected animals
    Dongmei Yang
    University of North Carolina School of Medicine, Department of Microbiology and Immunology, Chapel Hill, North Carolina, USA
    Genome Announc 1:e0005413. 2013
  8. pmc Prevention of maternal cytomegalovirus infection: current status and future prospects
    Jessica L Nyholm
    Department of Obstetrics, Gynecology, and Women s Health and
    Int J Womens Health 2:23-35. 2010
  9. pmc An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model
    Michael P Leviton
    Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, University of Minnesota Medical School, Center for Infectious Diseases and Microbiology Translational Research, 2001 6th Street SE, Minneapolis, MN 55455, USA
    Clin Dev Immunol 2013:906948. 2013
  10. pmc Molecular and biological characterization of a new isolate of guinea pig cytomegalovirus
    Mark R Schleiss
    Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Viruses 6:448-75. 2014

Collaborators

Detail Information

Publications65

  1. ncbi request reprint Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV)
    Mark R Schleiss
    Division of Infectious Diseases, Children s Hospital Research Foundation, Cincinnati, OH 45229, USA
    J Clin Virol 25:S37-49. 2002
    ..Therefore, recent efforts have been undertaken to characterize the GPCMV genome, and apply this information to in vivo subunit vaccine studies...
  2. ncbi request reprint An animal model of neonatal cytomegalovirus infection
    Fernando J Bravo
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
    Antiviral Res 60:41-9. 2003
    ..001) and viral replication but did not improve weight gain. This model should be useful for further evaluations of the pathogenesis of CMV infections and for evaluation of antiviral drugs and vaccines...
  3. pmc Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83)
    Alistair McGregor
    Division of Infectious Diseases, Children s Hospital Medical Center Research Foundation, University of Cincinnati, OH 45229, USA
    J Virol 78:9872-89. 2004
    ..The vAM409 mutant was significantly attenuated for dissemination in immunocompromised strain 2 guinea pigs, suggesting that the GP83 protein is essential for full pathogenicity in vivo...
  4. ncbi request reprint Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects
    Mark R Schleiss
    Division of Infectious Diseases, 3333 Burnet Avenue, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Vaccine 23:687-92. 2004
    ..These data reinforce the favorable safety profile of CMV gB vaccines...
  5. ncbi request reprint Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection
    Mark R Schleiss
    Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, Minneapolis, MN, 55455, USA
    J Infect Dis 195:789-98. 2007
    ..These results indicate that cell-mediated immune responses directed against a CMV matrix protein can protect against congenital CMV infection and disease...
  6. pmc Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model
    Mark R Schleiss
    Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Minneapolis, United States Electronic address
    Vaccine 32:2756-62. 2014
    ..In conclusion, the protective efficacy and immunogenicity of adjuvanted vaccines in this guinea pig model are supportive of investigating gB/AS01 and gB/AS02 in the clinic. ..
  7. pmc Complete genome sequence of pathogenic Guinea pig cytomegalovirus from salivary gland homogenates of infected animals
    Dongmei Yang
    University of North Carolina School of Medicine, Department of Microbiology and Immunology, Chapel Hill, North Carolina, USA
    Genome Announc 1:e0005413. 2013
    ..The 233,501-nucleotide salivary gland (SG) genome was noted to have 11 differences compared to the tissue culture-passaged virus, although no variations were noted in putative protein coding sequences...
  8. pmc Prevention of maternal cytomegalovirus infection: current status and future prospects
    Jessica L Nyholm
    Department of Obstetrics, Gynecology, and Women s Health and
    Int J Womens Health 2:23-35. 2010
    ..The epidemiology, clinical manifestations, prevention strategies, and treatment of CMV infections are reviewed...
  9. pmc An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model
    Michael P Leviton
    Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, University of Minnesota Medical School, Center for Infectious Diseases and Microbiology Translational Research, 2001 6th Street SE, Minneapolis, MN 55455, USA
    Clin Dev Immunol 2013:906948. 2013
    ..0001). We conclude that deletion of an immune modulation gene can attenuate the pathogenicity of GPCMV while resulting in a viral vaccine that retains immunogenicity and demonstrates efficacy against congenital infection and disease...
  10. pmc Molecular and biological characterization of a new isolate of guinea pig cytomegalovirus
    Mark R Schleiss
    Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Viruses 6:448-75. 2014
    ..The availability of a new GPCMV strain should facilitate study of re-infection in this small animal model. ..
  11. pmc Asymptomatic DNAemia heralds CMV-associated NEC: case report, review, and rationale for preemption
    Supatida Tengsupakul
    Department of Pediatrics, University of Minnesota, 2001 6th Street SE, Minneapolis, MN 55455
    Pediatrics 132:e1428-34. 2013
    ..Future studies should examine the potential utility of preemptive monitoring for, and possibly treatment of, CMV DNAemia in premature infants, which may herald the onset of serious disease...
  12. pmc Cytomegalovirus in the neonate: immune correlates of infection and protection
    Mark R Schleiss
    Department of Pediatrics, University of Minnesota Medical School, Center for Infectious Diseases and Microbiology Translational Research, 2001 6th Street SE, Minneapolis, MN 55455, USA
    Clin Dev Immunol 2013:501801. 2013
    ..A better understanding of immune responses that prevent and/or predispose to infection will help in the development of novel vaccine strategies...
  13. pmc Congenital cytomegalovirus infection: update on management strategies
    Mark R Schleiss
    Mark R Schleiss, MD Division of Infectious Diseases and Immunology, University of Minnesota Children s Hospital and Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, 2001 6th Street SE, Minneapolis, MN 55455, USA
    Curr Treat Options Neurol 10:186-92. 2008
    ..In the pregnant woman with primary CMV infection, the use of CMV-specific immune globulin, though still investigational, is garnering attention and may prove to be a valuable therapy...
  14. pmc Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis
    Mark R Schleiss
    Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Minneapolis, MN 55455, USA
    Infect Disord Drug Targets 11:449-65. 2011
    ..Areas for potential development of novel therapeutic intervention are suggested for improving the outcome of this disabling congenital infection...
  15. pmc Intravaginal cytomegalovirus (CMV) challenge elicits maternal viremia and results in congenital transmission in a guinea pig model
    Megan J Olejniczak
    Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, 2001 6th Street SE, Minneapolis, MN 55455, USA
    Virol J 8:89. 2011
    ..These studies tested the hypotheses that ivg infection would elicit immune responses, produce maternal viremia, and lead to vertical transmission, with an efficiency similar to the traditionally employed sc route...
  16. ncbi request reprint Acquisition of human cytomegalovirus infection in infants via breast milk: natural immunization or cause for concern?
    Mark R Schleiss
    Department of Paediatrics, Division of Paediatric Infectious Diseases and Immunology, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455, USA
    Rev Med Virol 16:73-82. 2006
    ....
  17. pmc Cytomegalovirus vaccine development
    M R Schleiss
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, 2001 6th Street SE, Minneapolis, MN 55455, USA
    Curr Top Microbiol Immunol 325:361-82. 2008
    ....
  18. pmc The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs
    Mark R Schleiss
    Division of Infectious Diseases, Children s Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Antiviral Res 65:35-43. 2005
    ..Mortality differences were accompanied by reduction in DNAemia in Hartley guinea pigs. Based upon its favorable safety, pharmacokinetic, and therapeutic profiles, BAY 38-4766 warrants further investigation in the GPCMV model...
  19. ncbi request reprint Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection
    Mark R Schleiss
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Pediatr 151:564-70. 2007
  20. ncbi request reprint Progress in cytomegalovirus vaccine development
    Mark Schleiss
    University of Minnesota School of Medicine, Department of Pediatrics, 620 Delaware Street SE, MMC 296, Minneapolis, MN 55455, USA
    Herpes 12:66-75. 2005
    ..Such questions must be answered before an optimal vaccine, and vaccine use strategy, can be implemented in clinical practice...
  21. ncbi request reprint Role of breast milk in acquisition of cytomegalovirus infection: recent advances
    Mark R Schleiss
    Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455, USA
    Curr Opin Pediatr 18:48-52. 2006
    ..The purpose of this review is to summarize recent studies of breast-milk-acquired cytomegalovirus infections in newborns, particularly in low-birth-weight premature infants...
  22. pmc Cyclic cidofovir (cHPMPC) prevents congenital cytomegalovirus infection in a guinea pig model
    Mark R Schleiss
    Division of Infectious Diseases, University of Minnesota Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, McGuire Translational Research Facility, Minneapolis, Minnesota 55455, USA
    Virol J 3:9. 2006
    ..The guinea pig model of congenital CMV infection was therefore used to test the hypothesis that antiviral therapy, using the agent agent cyclic cidofovir (cHPMPC), could prevent congenital CMV infection...
  23. ncbi request reprint Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine
    Mark R Schleiss
    Division of Infectious Diseases, University of Minnesota Medical School, Department of Pediatrics, Center for Infectious Diseases and Microbiology Translational Research, Minneapolis, MN 55455, United States
    Vaccine 24:6175-86. 2006
    ..005 versus control, Fisher's exact test). In addition, vaccinated dams had reduced viral load, compared to controls, as assessed by quantitative, real-time PCR...
  24. pmc Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome
    Mark R Schleiss
    Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Minneapolis, MN 55455, USA
    Virol J 5:139. 2008
    ..The sequence of GPCMV should facilitate vaccine and pathogenesis studies in this model of congenital CMV infection...
  25. ncbi request reprint Progress toward an elusive goal: current status of cytomegalovirus vaccines
    Mark R Schleiss
    University of Minnesota School of Medicine, 420 Delaware Street SE, MMC 296, Minneapolis, MN 55455, USA
    Expert Rev Vaccines 4:381-406. 2005
    ....
  26. ncbi request reprint Antiviral therapy of congenital cytomegalovirus infection
    Mark R Schleiss
    Division of Pediatric Infectious Diseases and Immunology, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA
    Semin Pediatr Infect Dis 16:50-9. 2005
    ..CMV vaccines, once available, may ultimately be the best control strategy for this important public health problem...
  27. ncbi request reprint Cytomegalovirus infection of human syncytiotrophoblast cells strongly interferes with expression of genes involved in placental differentiation and tissue integrity
    Mark R Schleiss
    Department of Pediatrics, Division of Infectious Diseases and Immunology, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Res 61:565-71. 2007
    ..An improved understanding of the molecular events that occur during CMV infection of trophoblasts could provide insights into interventions that might prevent or minimize congenital transmission...
  28. pmc Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines
    Mark R Schleiss
    Department of Pediatrics, University of Minnesota Medical School, Center for Infectious Diseases and Microbiology Translational Research, Minneapolis, Minnesota, USA
    J Clin Invest 120:4192-7. 2010
    ..Demonstration of the ability to engineer a safe and highly effective live virus vaccine in a relevant rodent model of CMV infection may open the door to clinical trials of safer and more immunogenic HCMV vaccines...
  29. ncbi request reprint Comparison of vaccine strategies against congenital CMV infection in the guinea pig model
    Mark R Schleiss
    Division of Pediatric Infectious Diseases and Immunology, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, 2001 6th Street SE, Minneapolis, MN 55455, USA
    J Clin Virol 41:224-30. 2008
    ....
  30. pmc Cytomegalovirus vaccines and methods of production (WO20009049138): the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface
    Mark R Schleiss
    University of Minnesota Medical School, Center for Infectious Diseases and Microbiology Translational Research, Department of Pediatrics, MN 55455, USA
    Expert Opin Ther Pat 20:597-602. 2010
    ..In this patent evaluation, the basis for this patent is reviewed. The potential application of this discovery for future CMV vaccine design is discussed...
  31. pmc VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection
    Mark R Schleiss
    University of Minnesota, Center for Infectious Diseases and Microbiology Translational Research, Department of Pediatrics, Minneapolis, MN 55455, USA
    Curr Opin Mol Ther 11:572-8. 2009
    ....
  32. ncbi request reprint Cytomegalovirus vaccines: at last, a major step forward
    Mark R Schleiss
    Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Herpes 15:44-5. 2009
    ..In no area has the lack of progress been more frustrating than in the realm of CMV vaccine development. Although a number of vaccine strategies have been considered, few have advanced to the stage of efficacy testing...
  33. ncbi request reprint Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection
    Mark R Schleiss
    Division of Infectious Diseases, Children s Hospital Research Foundation, Cincinnati, Ohio 45229, USA
    J Infect Dis 188:1868-74. 2003
    ..These data support the concept that subunit gB vaccination may be useful in protecting against CMV-induced disease...
  34. ncbi request reprint Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine
    Mark R Schleiss
    Division of Infectious Diseases, Children s Hospital Research Foundation, Cincinnati, Ohio 45229, USA
    J Infect Dis 189:1374-81. 2004
    ..These are the first data indicating that a recombinant gB vaccine protects against congenital CMV infection and disease...
  35. ncbi request reprint Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo
    Mark Schleiss
    Center for Infectious Diseases and Microbiology Translational Research, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA
    Antiviral Res 79:49-61. 2008
    ..In contrast to the in vitro data, Ax7396 showed no significant antiviral activity in a mouse model. Further in vivo analyses have to assess the potential use of gefitinib in the treatment of cytomegalovirus disease...
  36. ncbi request reprint A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines
    Thomas C Heineman
    Division of Infectious Diseases and Immunology, Saint Louis University School of Medicine, St Louis, Missouri 63110, and Division of Pediatric Infectious Diseases, Children s Hospital Medical Center, University of Cincinnati, OH, USA
    J Infect Dis 193:1350-60. 2006
    ..Although not evaluated for this indication, live attenuated HCMV vaccines based on the Towne strain are well-tolerated and have demonstrated moderate efficacy in other clinical settings...
  37. ncbi request reprint Quantitative-competitive PCR monitoring of viral load following experimental guinea pig cytomegalovirus infection
    Mark R Schleiss
    Cincinnati Children s Hospital Medical Center, Division of Infectious Diseases, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
    J Virol Methods 108:103-10. 2003
    ..Viral load determination should be useful for monitoring outcomes following vaccine studies, as well as responses to experimental antiviral agents...
  38. ncbi request reprint Macrophage inflammatory proteins in cytomegalovirus-related inner ear injury
    Scott A Schraff
    Department of Pediatric Otolaryngology Head and Neck Surgery, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
    Otolaryngol Head Neck Surg 137:612-8. 2007
    ..The purpose of the study was to determine if a virally encoded macrophage inflammatory protein played a role in CMV-related hearing loss...
  39. ncbi request reprint Identification of essential and non-essential genes of the guinea pig cytomegalovirus (GPCMV) genome via transposome mutagenesis of an infectious BAC clone
    Alistair McGregor
    Department of Molecular Genetics, University of Cincinnati School of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    Virus Res 101:101-8. 2004
    ....
  40. ncbi request reprint Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults
    David I Bernstein
    Division of Infectious Diseases, Children s Hospital Medical Center, CH 1, 3333 Burnet Ave Rm 1345, Cincinnati, Ohio 45229 3039, USA
    J Infect Dis 185:686-90. 2002
    ..All 3 vaccine regimens induced high-titer antibody and lymphoproliferative responses, but no benefit for priming or simultaneous vaccination was detected...
  41. ncbi request reprint Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection
    Mark R Schleiss
    Division of Infectious Diseases, Children s Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    J Virol Methods 108:59-65. 2003
    ..Recombinant GPCMV gB expressed in insect cells should prove useful in defining correlates of protective immunity in the GPCMV congenital infection model...
  42. ncbi request reprint Vertically transmitted herpesvirus infections
    Mark R Schleiss
    Children s Hospital Medical Center, Division of Infectious Diseases, Cincinnati, OH, USA
    Herpes 10:4-11. 2003
    ....
  43. pmc Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir
    Alistair McGregor
    Division of Pediatric Infectious Diseases, University of Minnesota Medical School, Center for Infectious Diseases and Microbiology Translational Research, 2001 6th Street SE, Minneapolis, MN 55455, United States
    Antiviral Res 78:250-9. 2008
    ..Additionally, GPCMV::UL97 exhibited improved susceptibility to another antiviral undergoing clinical trials, maribavir (MBV; benzimidazole riboside 1263W94), which also acts through UL97...
  44. ncbi request reprint Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency
    Samuel C Blackman
    Pediatric Residency Training Program, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    J Pediatr Hematol Oncol 26:601-5. 2004
    ..Serial genotypic analyses revealed multiple UL97 and UL54 (DNA polymerase) mutations that conferred phenotypic resistance to all currently licensed systemic CMV antivirals...
  45. ncbi request reprint Breast milk as a source for acquisition of cytomegalovirus (HCMV) in a premature infant with sepsis syndrome: detection by real-time PCR
    Benjamin T Kerrey
    Pediatric Residency Training Program, Children s Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    J Clin Virol 35:313-6. 2006
    ..Real-time PCR may be a useful tool in the evaluation of HCMV viral load in breast milk...
  46. pmc Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication
    Xiaohong Cui
    Department of Pediatrics, Virginia Commonwealth University School of Medicine, P O Box 980163, Richmond, VA, 23298 0163, United States
    J Virol Methods 149:231-9. 2008
    ..It should provide a valuable tool for evaluating the impact of genetic modifications on the safety and efficacy of live attenuated vaccines and for identifying genes important for congenital transmission and fetal disease...
  47. ncbi request reprint Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns
    Mark R Schleiss
    Division of Pediatric Infectious Diseases, University of Minnesota Children s Hospital, and School of Medicine, Department of Pediatrics, Minneapolis, MN, USA
    ILAR J 47:65-72. 2006
    ....
  48. ncbi request reprint Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy
    Mark R Schleiss
    Pediatrics and Molecular and Developmental Biology, Children s Hospital Research Foundation, Cincinnati, Ohio 45229, USA
    Expert Rev Anti Infect Ther 2:389-403. 2004
    ..Ultimately, the problem of perinatal CMV infection may be best controlled by the development of CMV vaccines, which could be administered to young women of childbearing age to help control this important public health problem...
  49. pmc The impact of genome length on replication and genome stability of the herpesvirus guinea pig cytomegalovirus
    Xiaohong Cui
    Department of Pediatrics, Virginia Commonwealth University School of Medicine P O Box 980163, Richmond Virginia 23298 0163, USA
    Virology 386:132-8. 2009
    ..These results suggest that genome integrity should be confirmed for herpesvirus mutants in which genome length is increased even modestly...
  50. pmc Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention
    Maxim C J Cheeran
    Departments of Medicine, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Clin Microbiol Rev 22:99-126, Table of Contents. 2009
    ..The prospects for intervention, including antiviral therapies and vaccines, are summarized. Priorities for future research are suggested to improve the understanding of this common and disabling illness of infancy...
  51. ncbi request reprint A novel CC-chemokine homolog encoded by guinea pig cytomegalovirus
    Shannon M Haggerty
    Department of Biological Sciences, Xavier University, Cincinnati, OH, USA
    Virus Genes 25:271-9. 2002
    ..This is the first identification of a CK gene encoded by GPCMV, and adds to the growing list of putative CMV immunomodulatory genes which appear to have been transduced from the host genome during the co-evolution of host and pathogen...
  52. ncbi request reprint Detection of cytomegalovirus DNA in dried blood spots of Minnesota infants who do not pass newborn hearing screening
    K Yeon Choi
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455 0374, USA
    Pediatr Infect Dis J 28:1095-8. 2009
    ..Early diagnosis linking virologic identification of congenital CMV infection to infants failing NHS may improve diagnostic precision and enhance opportunities for therapeutic intervention...
  53. ncbi request reprint The role of CMV inflammatory genes in hearing loss
    Scott A Schraff
    Department of Pediatric Otolaryngology Head and Neck Surgery, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Otol Neurotol 28:964-9. 2007
    ..The purpose of this study is to test the hypothesis that virally encoded immunomodulatory genes play a role in cytomegalovirus (CMV)-related hearing loss...
  54. ncbi request reprint Audiometric, clinical and educational outcomes in a pediatric symptomatic congenital cytomegalovirus (CMV) population with sensorineural hearing loss
    Colm Madden
    Center of Hearing and Deafness Research, Division of Otolaryngology Head and Neck Surgery, Department of Pediatric Otolaryngology, OSB 3, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Int J Pediatr Otorhinolaryngol 69:1191-8. 2005
    ..To correlate audiometric findings and outcomes with the clinical, radiological and educational findings in a symptomatic congenital cytomegalovirus (CMV) population with sensorineural hearing loss...
  55. ncbi request reprint Glycoprotein B genotyping of cytomegalovirus strains isolated in a pediatric population
    Stavra A Xanthakos
    Division of Infectious Diseases, Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Pediatr Infect Dis J 22:462-3. 2003
    ..Among 61 isolates glycoprotein B genotype distribution was genotype 1, 32%; genotype 2, 24%; genotype 3, 32%; and genotype 4, 10%. Among viremic isolates there was a trend favoring type 1 genotype (P = 0.057)...
  56. pmc Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation
    Jill C Beck
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 16:215-22. 2010
    ..01) and lower OS (P=.02). Thus, although recipient CMV serostatus and CMV reactivation have little demonstrable impact on UCB transplant outcomes, the development of CMV disease remains a risk, associated with inferior outcomes...
  57. ncbi request reprint Nonimmune hydrops fetalis and fulminant fatal disease due to congenital cytomegalovirus infection in a premature infant
    Venkatesh Sampath
    Department of Pediatrics, Division of Neonatology, Cincinnati Children s Hospital Medical Center, and Department of Pathology, University of Cincinnati School of Medicine, OH, USA
    J Perinatol 25:608-11. 2005
    ..Autopsy findings revealed the presence of widespread CMV disease, including pneumonitis, enteritis, and myocarditis. Congenital CMV infection should be considered in the differential diagnosis of hydrops fetalis...
  58. ncbi request reprint Bacterial meningitis from Rothia mucilaginosa in patients with malignancy or undergoing hematopoietic stem cell transplantation
    Alisa B Lee
    University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Pediatr Blood Cancer 50:673-6. 2008
    ..mucilaginosa meningitis in oncology and stem cell transplant patients, and provide updated recommendations regarding the use of antibiotic therapy in this patient population...
  59. ncbi request reprint Herpesvirus genome mutagenesis by transposon-mediated strategies
    Alistair McGregor
    Department of Molecular Genetics, University of Cincinnati School of Medicine, OH, USA
    Methods Mol Biol 256:281-302. 2004
  60. ncbi request reprint The role of the placenta in the pathogenesis of congenital cytomegalovirus infection: is the benefit of cytomegalovirus immune globulin for the newborn mediated through improved placental health and function?
    Mark R Schleiss
    Clin Infect Dis 43:1001-3. 2006
  61. ncbi request reprint The effect of cidofovir on cytomegalovirus-induced hearing loss in a Guinea pig model
    David R White
    Department of Otolaryngology Head and Neck Surgery, Medical University of South Carolina, Charleston, USA
    Arch Otolaryngol Head Neck Surg 132:608-15. 2006
    ..To evaluate the utility of therapy with the cyclic cogener of the anti-cytomegalovirus (CMV) agent cidofovir against CMV-induced hearing loss in a guinea pig model...
  62. ncbi request reprint Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease
    Rebecca C Brandy
    Department of Pediatrics Cincinnati Children s Hospital Medical Center, Cincinati, OH, USA
    Pediatr Infect Dis J 21:796-7. 2002
    ..4-kg girl. Examination of the placenta revealed transplacental passage of CMV. Low concentrations of ganciclovir were detected in the neonate's plasma. The neonate had mild anemia but no other signs of congenital CMV infection...
  63. ncbi request reprint A macrophage inflammatory protein homolog encoded by guinea pig cytomegalovirus signals via CC chemokine receptor 1
    Mark Penfold
    ChemoCentryx, San Carlos, CA 94070, USA
    Virology 316:202-12. 2003
    ..These results represent the first substantive in vitro characterization of a functional CC CK encoded by a cytomegalovirus...
  64. ncbi request reprint Sustained expression of human cytomegalovirus glycoprotein B (UL55) in the seeds of homozygous rice plants
    Eilleen S Tackaberry
    Sir Frederick Banting Research Centre, Health Canada, Ottawa, ON, Canada
    Mol Biotechnol 40:1-12. 2008
    ..Results show that immunoreactive gB was successfully expressed in transgenic rice seeds, with sustained expression over three generations. The gB contained several neutralizing epitopes and was stable over 27 months...

Research Grants18

  1. VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV
    Mark Schleiss; Fiscal Year: 2009
    ..We anticipate that these subunit vaccine studies in this small animal model will clarify which strategies may be of value for vaccination against congenital HCMV infection. ..
  2. Transgenic Plant-Derived CMV Glycoprotein B Vaccine
    Mark Schleiss; Fiscal Year: 2007
    ..These studies will advance the fields of plant and CMV vaccines. ..
  3. Novel Strategy for Animal Model Testing of HCMV Vaccines
    Mark Schleiss; Fiscal Year: 2007
    ..These studies will represent the first efficacy test of a human CMV subunit vaccine in a small animal model of congenital CMV infection. ..
  4. Viral Immunomodulation and Rational CMV Vaccine Design
    Mark Schleiss; Fiscal Year: 2007
    ..abstract_text> ..
  5. VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV
    Mark Schleiss; Fiscal Year: 2007
    ..We anticipate that these subunit vaccine studies in this small animal model will clarify which strategies may be of value for vaccination against congenital HCMV infection. ..
  6. VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV
    Mark Schleiss; Fiscal Year: 2006
    ..We anticipate that these subunit vaccine studies in this small animal model will clarify which strategies may be of value for vaccination against congenital HCMV infection. ..
  7. Viral Immunomodulation and Rational CMV Vaccine Design
    Mark Schleiss; Fiscal Year: 2006
    ..abstract_text> ..
  8. Viral Immunomodulation and Rational CMV Vaccine Design
    Mark Schleiss; Fiscal Year: 2004
    ..abstract_text> ..
  9. VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV
    Mark Schleiss; Fiscal Year: 2005
    ..We anticipate that these subunit vaccine studies in this small animal model will clarify which strategies may be of value for vaccination against congenital HCMV infection. ..
  10. Viral Immunomodulation and Rational CMV Vaccine Design
    Mark Schleiss; Fiscal Year: 2005
    ..abstract_text> ..
  11. Viral Immunomodulation and Rational CMV Vaccine Design
    Mark Schleiss; Fiscal Year: 2004
    ..abstract_text> ..
  12. Viral Immunomodulation and Rational CMV Vaccine Design
    Mark Schleiss; Fiscal Year: 2003
    ..abstract_text> ..
  13. VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV
    Mark Schleiss; Fiscal Year: 2003
    ..abstract_text> ..
  14. VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV
    Mark Schleiss; Fiscal Year: 2002
    ..abstract_text> ..
  15. VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV
    Mark Schleiss; Fiscal Year: 2001
    ..abstract_text> ..
  16. VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMV
    Mark Schleiss; Fiscal Year: 2000
    ..abstract_text> ..